Skip to main content

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Primärliteratur

  1. Oettgen HF, Stephenson PA, Schwartz MK, et al: Toxicity of E. coli L-asparaginase in man. Cancer 25: 253–278, 1970.

    CAS  Google Scholar 

  2. Haskell CM, Canellos GP, Leventhal BG, et al: L-Asparaginase: therapeutic and toxic effects in patients with neoplastic disease. N Engl J Med 281: 1028–1034, 1969.

    Article  PubMed  CAS  Google Scholar 

  3. Barr RD, Benton SG, Belbeck LW: Soft-tissue necrosis induced by extravasated cancer chemotherapeutic agents. J Natl Cancer Inst 66: 1129–1136, 1981.

    PubMed  CAS  Google Scholar 

Sekundärliteratur

  1. Dorr RT: Antidotes to vesicant chemotherapy extravasations. Blood Rev 4: 41–60, 1990.

    Article  PubMed  CAS  Google Scholar 

  2. Stanley A: Managing complications of chemotherapy. In: Allwood M, Stanley A, Wright P (eds) The Cytotoxics Handbook. Radcliffe Medical Press, 3rd edition: 105–124, 1997.

    Google Scholar 

  3. Schneider G: Paravasate von Zytostatika. Diagnostik und Therapie. Aina S. Schneider Verlag, 6. Auflage: 1–17, 1999.

    Google Scholar 

  4. Schneider SM, Distelhorst CW: Chemotherapy-induced emergencies. Semin Oncol 16: 572–578, 1989.

    PubMed  CAS  Google Scholar 

  5. Ignoffo RJ, Friedman MA: Therapy of local toxicities caused by extravasation of cancer chemotherapeutic drugs. Cancer Treat Rev 7: 17–27, 1980.

    Article  PubMed  CAS  Google Scholar 

  6. Dorr RT: Pharmacologic management of vesicant chemotherapy extravasations. In: Dorr RT, Von Hoff DD (eds) Cancer Chemotherapy Handbook. Appleton & Lange, 2nd edition: 109–118, 1994.

    Google Scholar 

  7. Cox K, Stuart-Harris R, Abdini G, et al: The management of cytotoxic-drug extravasation: guide-lines drawn up by a working party for the Clinical Oncological Society of Australia. Med J Aust 148: 185–189, 1988.

    PubMed  CAS  Google Scholar 

  8. Fuxius S, Unger C: Pegaspargase. Arzneimitteltherapie 16: 170–173, 1998.

    Google Scholar 

  9. Gain M, Melzer S, Meyer-Jürshof A, et al: Allgemeiner Teil: Behandlung von Paravasaten. In: Gain M, et al (Hrsg) ADKA-Zytostatika-Handbuch, Pharmazeutisch-wissenschaftliche Monographien. Verlag Heiner Biller, Band 1, 2. Auflage: A42–44, 1997.

    Google Scholar 

  10. Dorr RT, Von Hoff DD: Drug monographs: Asparaginase. In: Dorr RT, Von Hoff DD (eds) Cancer Chemotherapy Handbook. Appleton & Lange, 2nd edition: 201–209, 1994.

    Google Scholar 

  11. Fachinformation Asparaginase medac (Deutschland), Medac, Sepember 1995.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer-Verlag Wien

About this chapter

Cite this chapter

Mader, I., Fürst-Weger, P., Mader, R.M., Semenitz, E.I., Terkola, R., Wassertheurer, S.M. (2002). L-Asparaginase. In: Paravasation von Zytostatika. Springer, Vienna. https://doi.org/10.1007/978-3-7091-3799-4_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-3799-4_7

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-7091-3800-7

  • Online ISBN: 978-3-7091-3799-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics